| |APRIL 20268TOP STORIESBHARAT PARENTERALS ARM GETS FIVE USFDA OBSERVATIONS AFTER AUDITINDIA LEADS GLOBAL SHIFT TOWARD AI-DRIVEN PERSONAL HEALTH CAREMERCK KEYTRUDA COMBO ADVANCES IN BLADDER CANCER TREATMENTASTER CMI HOSPITAL LAUNCHES 'PEARL', A DEDICATED PEDIATRIC LIVER ICUNEW AMMONIA RULE IN INDIA SQUEEZES PHARMA RAW MATERIAL SUPPLYBharat Parenterals Ltd said its subsidiary, Innoxel Lifesciences, has received five observations from the United States Food and Drug Administration (USFDA) following a recent USFDA inspection at its Vadodara facility.The inspection was carried out between April 13 and April 17, 2026, at the company's General Injectables Block, and concluded on April 20. At the end of the review, the USFDA issued five observations under the Voluntary Action Indicated (VAI) category. This classification typically means that while certain issues were identified, they are not serious enough to trigger immediate regulatory action. POIndia is steadily emerging as a global leader in using artificial intelligence in healthcare, thanks to its strong digital growth, increasing health awareness, and rising investments in health technology. As AI becomes a part of everyday life, India's healthcare system is adapting quickly to make care more personalized healthcare, efficient, and accessible for people.Merck has secured a key step forward as the Merck KEYTRUDA FDA priority review gains momentum in bladder cancer treatment.The US Food and Drug Administration has granted priority review for KEYTRUDA and KEYTRUDA QLEX, both evaluated in combination with Padcev. The applications target patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy.The FDA has set a Prescription Drug User Fee Act target action date of August 17, 2026. If approved, the combination could become the first perioperative treatment option for MIBC across both cisplatin-eligible and ineligible patients, expanding beyond its current use limited to those unable to receive cisplatin. POIn a significant step toward transforming pediatric critical care, Aster CMI Hospital today announced the launch of PEARL (Pediatric Emergency and Advanced Response for Liver Care) ­ Karnataka's first dedicated Pediatric Liver Intensive Care Unit (ICU).This specialized unit has been purpose-built to exclusively manage children with severe and life-threatening liver conditions, bringing a new level of focused, timely, and highly specialized care to pediatric healthcare.The unit was inaugurated by M Maheshwar Rao (IAS), Chief Commissioner, Greater Bengaluru Authority (GBA), in the presence of senior leadership and clinical experts from Aster Hospitals. POIndia's ammonia rule is tightening the availability of a key raw material for pharmaceutical companies, after the government directed that surplus ammonia from urea plants be reserved primarily for fertilizer production.The move is aimed at protecting agricultural supply, but it is now raising concerns across the drug manufacturing sector.Ammonia is widely used in the production of active pharmaceutical ingredients, making it essential for bulk drug manufacturing. POToday, many individuals are using AI-powered tools to better understand and manage their health. Wearable health devices can track heart rate, sleep, and activity levels, while mobile apps offer personalised suggestions based on individual health data. This shift is helping people move from treating illnesses after they occur to preventive healthcare. PO
< Page 7 | Page 9 >